Search

Arcus Biosciences Inc

Deschisă

SectorSănătate

22.48 -7.22

Rezumat

Modificarea prețului

24h

Curent

Minim

23.25

Maxim

24.56

Indicatori cheie

By Trading Economics

Venit

37M

-91M

Vânzări

24M

41M

EPS

-0.72

Marjă de profit

-221.951

Angajați

601

EBITDA

38M

-85M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+58.59% upside

Dividende

By Acuity

Următoarele câștiguri

26 oct. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-362M

3.1B

Deschiderea anterioară

29.7

Închiderea anterioară

22.48

Arcus Biosciences Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

8 oct. 2026, 20:07 UTC

Arcus Biosciences Inc shares are declining, closing significantly lower since Wednesday and near the bottom of their one-month range after an earlier session pullback.

7 oct. 2026, 19:46 UTC

Arcus Biosciences Inc shares are higher, having gained ground but remain below their 20-day moving average and near the lower end of their one-month range.

6 oct. 2026, 20:30 UTC

Arcus Biosciences Inc's shares declined in after-market trading, currently at their lowest point of the day and well below the 20-day moving average.

5 oct. 2026, 20:06 UTC

News

Arcus Biosciences Inc is advancing, supported by broader market movements, and has gained since Friday's close, despite earlier pulling back from a session high.

2 oct. 2026, 20:02 UTC

Arcus Biosciences Inc shares fell sharply, reversing earlier gains, and remain below their 20-day moving average amid ongoing weakness.

1 oct. 2026, 20:08 UTC

Correlated Moves

Nektar Therapeutics' disappointing Phase 2b study results contributed to a broader downturn in biotechnology, with the SPDR S&P Biotech ETF also lower.

30 sept. 2026, 20:07 UTC

News

Arcus Biosciences Inc shares are advancing modestly as Wedbush reiterates its Outperform rating and maintains a $43 price target.

29 sept. 2026, 20:07 UTC

Arcus Biosciences Inc is advancing, reflecting a notable increase since Monday's close, although it remains below its 20-day moving average.

28 sept. 2026, 19:15 UTC

Arcus Biosciences Inc is advancing, having reached a notable peak today, despite trading below its 20-day moving average and three prior sessions closing lower.

25 sept. 2026, 23:50 UTC

Arcus Biosciences Inc is trading lower in after-hours, reaching its lowest point of the day and remaining well below its 20-day moving average.

24 sept. 2026, 20:01 UTC

Arcus Biosciences Inc shares fell sharply, continuing a downward trend from Wednesday's close and trading well below its 20-day moving average.

23 sept. 2026, 20:07 UTC

Correlated Moves

Arcus Biosciences Inc shares fell amid a broader market downturn and rising U.S. Treasury yields, despite earlier reaching a session high.

22 sept. 2026, 20:06 UTC

Arcus Biosciences Inc is advancing amid a strong biotechnology sector, gaining ground since Monday's close but remains below its 20-day moving average.

21 sept. 2026, 19:16 UTC

Arcus Biosciences Inc is trading higher since Friday's close, despite being below its 20-day moving average and near the lower end of its one-month range.

18 sept. 2026, 20:13 UTC

Arcus Biosciences Inc is advancing in after-market trading following Friday's close, despite being positioned below its 20-day moving average.

17 sept. 2026, 19:36 UTC

Correlated Moves

Arcus Biosciences is advancing, building on prior momentum, amid a broader biotech sector uptick driven by positive Phase 3 results from Moderna's cancer vaccine trial.

16 sept. 2026, 23:06 UTC

Arcus Biosciences Inc is trading slightly higher in after-market hours, recovering from an earlier dip but remains below its 20-day moving average.

15 sept. 2026, 19:36 UTC

Correlated Moves

RCUS lower today, tracking declines in SPDR S&P Biotech ETF.

14 sept. 2026, 20:21 UTC

Arcus Biosciences Inc shares are lower in after-market hours, marking seven consecutive sessions of declines. No specific news was identified for the price movement.

11 sept. 2026, 21:21 UTC

Arcus Biosciences Inc shares are lower in after-market trading, continuing a recent trend. No specific company news was identified to explain the decline.

10 sept. 2026, 20:01 UTC

Arcus Biosciences Inc shares are sharply lower today, breaking a recent trend of higher closes. Unusually high trading volume may be influencing the decline.

9 sept. 2026, 20:07 UTC

News

Shares of Arcus Biosciences are lower today, despite anticipation of a significant data update in October following a recent presentation at Citigroup's summit.

8 sept. 2026, 20:07 UTC

Arcus Biosciences Inc shares are lower today, continuing a decline since Friday's close. The stock is trading near the lower end of its one-month range.

2 sept. 2026, 20:08 UTC

Correlated Moves

Arcus Biosciences Inc. shares are higher today, supported by gains in the biotechnology sector and trends in related ETFs. The stock has stabilized after fluctuations.

28 aug. 2026, 20:02 UTC

Arcus Biosciences shares are lower today, breaking a trend of higher closes. Rising U.S. Treasury yields may be impacting investor sentiment in biotechnology.

26 aug. 2026, 20:08 UTC

Arcus Biosciences Inc shares are lower during Wednesday's session amid mixed market performance and inflation data, with no specific company news identified for the decline.

20 aug. 2026, 19:36 UTC

Correlated Moves

Arcus Biosciences shares are lower, reflecting a broader decline in the biotechnology sector amid first-quarter results indicating a notable drop in price.

19 aug. 2026, 19:46 UTC

Correlated Moves

Arcus Biosciences Inc is trading higher, supported by a positive trend in the biotechnology sector. The stock remains above its 20-day moving average.

18 aug. 2026, 20:06 UTC

Arcus Biosciences Inc. shares are trading roughly flat amid no specific news. The stock remains above its 20-day moving average.

17 aug. 2026, 19:16 UTC

News

Arcus Biosciences Inc is rising as biotechnology sector momentum continues. The company reported second-quarter revenue of $41 million and a net loss of $91 million.

Comparație

Modificare preț

Arcus Biosciences Inc Așteptări

Obiectiv de preț

By TipRanks

58.59% sus

Prognoză pe 12 luni

Medie 38.6 USD  58.59%

Maxim 47 USD

Minim 23 USD

În baza a 11 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruArcus Biosciences Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

11 ratings

8

Cumpărare

3

Păstrare

0

Vânzare

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.
help-icon Live chat